Zacks Advises Holding TNDM Despite Persistent Challenges and Competitive Pressures

What happened

On March 13, 2026, Zacks Investment Research recommended holding Tandem Diabetes Care stock, citing new pump launches, CGM integrations, and strong solvency as growth supports. However, a DeepValue master report indicates that while TNDM has shown gross margin improvement to the mid-50s and positive operating cash flow in Q3 2025, it remains unprofitable with negative EBITDA and faces intense competition from Medtronic and Insulet. The company's growth is increasingly reliant on consumables sales rather than new pump units, and it has navigated a high-severity recall for the t:slim X2 pump, adding regulatory risk. DeepValue rates TNDM as a 'WAIT' with an attractive entry at $18, emphasizing the need for confirmation of 2026 growth and margin targets before accumulating. Thus, Zacks' hold call aligns with a cautious outlook, but investors must critically assess ongoing execution risks and external headwinds like CMS competitive bidding and GLP-1 adoption pressures.

Implication

For current holders, maintaining a position is reasonable given potential upside from margin expansion and new product launches, but portfolio sizing should be conservative due to high volatility and negative earnings. New investors should wait for a lower entry price around $18 or until the company hits its $1 billion revenue target and shows consistent positive free cash flow, as advised by DeepValue. Key risks include failure to achieve the 60% gross margin target by end-2026, further safety recalls, and intensified pricing pressure from CMS and competitors like Medtronic and Insulet. Monitoring quarterly results, especially gross margins and cash flow, along with updates on the Mobi pharmacy rollout and Control-IQ+ adoption, is crucial for timing any entry. Overall, the investment case hinges on management's ability to execute a challenging turnaround amidst a tough competitive landscape, warranting a patient and selective approach rather than aggressive buying.

Thesis delta

The Zacks hold recommendation does not materially alter the DeepValue thesis, which already suggests waiting due to high uncertainty and execution dependency in TNDM's turnaround. Any upward shift would require confirmation of 2026 targets such as resumed pump growth and margin expansion, but current data shows persistent losses and competitive pressures. Investors should remain in wait-and-see mode until clearer evidence emerges from upcoming earnings and operational milestones.